Phencyclidine (PCP): A Dangerous Drug, but Useful in Schizophrenia Research

Abstract Phencyclidine (PCP) is a dangerous drug, and the federal government has placed it on Schedule II of the Controlled Substance Act (see http://www.mninter.net/∼publish/csa2.htm#Schedule%20III). Typically, users smoke PCP, and it is often mixed with parsley, marijuana, or cocaine. Most researchers have conducted experiments on animals rather than on people, and a few have been done on persons diagnosed with schizophrenia, so answers to questions about its addictive potential or development of tolerance are not clear. In healthy volunteers, PCP can induce symptoms that mimic those of schizophrenia, lasting from a few days to more than a week. The neurotransmitter glutamate and N-methyl-D-aspartate (NMDA) appear to play a role in the mechanism by which PCP induces positive and negative schizophrenic symptoms and cognitive defects (D. C. Javitt & S. R. Zukin, 1991; A. Lahti, B. Koffel, D. LaPorte, & C. A. Tarnminga, 1995; T. W. Robbins, 1990). Because PCP can induce symptoms that are almost indistinguishable from those associated with schizophrenia, further research may lead to new medications that could be helpful to people who do not respond to neuroleptics that are currently available.

[1]  J. Km Neurochemical pharmacology of phencyclidine. , 1978 .

[2]  T. Robbins,et al.  The case of frontostriatal dysfunction in schizophrenia. , 1990, Schizophrenia bulletin.

[3]  B. Leonard,et al.  Some effects of an hallucinogenic drug (phencyclidine) on neurohumoral substances. , 1970, Life sciences. Pt. 1: Physiology and pharmacology.

[4]  R. Balster Clinical implications of behavioral pharmacology research on phencyclidine. , 1986, NIDA research monograph.

[5]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[6]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[7]  A. Awad,et al.  Psychopharmacology: The Fourth Generation of Progress , 1998, CNS Spectrums.

[8]  D. Gorelick,et al.  Diagnosis and treatment of chronic phencyclidine (PCP) abuse. , 1986, NIDA research monograph.

[9]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[10]  D. Javitt,et al.  Phencyclidine receptor binding as a probe of NMDA receptor functioning: implications for drug abuse research. , 1993, NIDA research monograph.

[11]  J. Salamone,et al.  The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study , 1993, Brain Research.

[12]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[13]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[14]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[15]  R. Roth,et al.  Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. , 1997, Science.

[16]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[17]  Balster Rl Clinical implications of behavioral pharmacology research on phencyclidine. , 1986 .

[18]  Luisada Pv The phencyclidine psychosis: phenomenology and treatment. , 1978 .

[19]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[20]  R. Crider Phencyclidine: changing abuse patterns. , 1986, NIDA research monograph.

[21]  R. Peele Phencyclidine (PCP) Abuse: An Appraisal. NIDA Research Monograph 21 , 1979 .

[22]  Michael F. Green,et al.  48 NEUROCOGNITIVE FUNCTIONING IN PATIENTS WITH SCHIZOPHRENIA : AN OVERVIEW , 2002 .

[23]  I. Wickelgren A New Route to Treating Schizophrenia? , 1998, Science.

[24]  B. Moghaddam,et al.  Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine , 1998, The Journal of Neuroscience.

[25]  R. Roth,et al.  Phencyclidine Increases Forebrain Monoamine Metabolism in Rats and Monkeys: Modulation by the Isomers of HA966 , 1997, The Journal of Neuroscience.

[26]  W. Woolverton,et al.  Continuous-access phencyclidine self-administration by rhesus monkeys leading to physical dependence , 2004, Psychopharmacology.

[27]  D. Pitts,et al.  Psychopharmacology of phencyclidine. , 1986, NIDA research monograph.

[28]  Lewis Je,et al.  Neuropsychological assessment of phencyclidine abusers. , 1986 .

[29]  R. Waziri,et al.  Evidence of glutamatergic deficiency in schizophrenia , 1991, Neuroscience Letters.

[30]  Karl J. Friston,et al.  Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia , 1995, Nature.

[31]  P. V. Luisada The phencyclidine psychosis: phenomenology and treatment. , 1978, NIDA research monograph.

[32]  L. Snell,et al.  Involvement of dopaminergic, cholinergic, and glutamatergic mechanisms in the actions of phencyclidine-like drugs. , 1986, NIDA research monograph.

[33]  K. Johnson,et al.  Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. , 1990, Annual review of pharmacology and toxicology.